MADISON, Wis. / Oct 08, 2024 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
| Third quarter 2024 webcast & conference call details | |||
Date: | Tuesday, November 5, 2024 | ||
Time: | 5 p.m. ET | ||
Webcast: | The live webcast can be accessed at www.exactsciences.com | ||
Telephone: | Domestic callers, dial 888-330-2384 | ||
| International callers, dial +1 240-789-2701 | ||
| Access code for both domestic and international callers: 4437608 | ||
A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.
About Exact Sciences Corp.
A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.
| Last Trade: | US$61.25 |
| Daily Change: | 1.89 3.18 |
| Daily Volume: | 931,995 |
| Market Cap: | US$11.600B |
September 10, 2025 August 06, 2025 August 06, 2025 July 31, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
